OAB Causing Urgency,
Leakage, and Lost Sleep?
Overactive bladder affects 33 million Americans — but most patients don't know that a long-term, minimally invasive solution exists beyond pills and pads. Bladder Centers of America specializes in sacral neuromodulation: the highest-ranked OAB therapy in head-to-head clinical evidence.
What the research says about overactive bladder and SNM
What is overactive bladder —
and why doesn't it just go away?
Overactive bladder (OAB) is a syndrome — not a single disease — defined by a cluster of urinary symptoms driven by abnormal nerve signaling between the bladder and the brain. The bladder muscle contracts involuntarily, before it's full, producing sudden urgency that can be difficult or impossible to defer.
According to the Urology Care Foundation, OAB affects at least 33 million Americans — more than asthma, diabetes, or osteoporosis — yet most patients suffer for years before seeking care, assuming little can be done. That assumption is wrong.
OAB is diagnosed as a symptom-based syndrome, meaning no single test confirms it — the combination of urgency, frequency, and nocturia (with or without leakage) is what clinicians look for. Underlying causes can include nerve damage, hormonal changes, infections, medications, or neurological conditions — but often no identifiable cause is found.
The important distinction: OAB is a nerve communication problem, not a structural one. That's why behavioral therapy and medications produce limited long-term results, and why sacral neuromodulation — which targets the nerve itself — is ranked #1 of all OAB therapies in the evidence.
Leakage from physical pressure
- Triggered by cough, sneeze, exercise
- Structural / sphincter issue
- Responds to pelvic floor therapy
- Not typically treated with SNM
Urgency from a nerve signal problem
- Sudden, overwhelming urge to void
- Bladder contracts before it's full
- Often fails to respond to medication
- SNM is ranked #1 in head-to-head evidence
✦ The OAB Triad
OAB is typically characterized by three core symptoms: urgency (sudden urge), frequency (>8 voids/day), and nocturia (waking ≥2×/night) — with or without urge incontinence (leakage). Not everyone has all three, but most have at least two.
The symptoms of overactive bladder —
do any of these sound familiar?
OAB presents differently in different people. These are the most common patterns our patients describe.
Urinary urgency
A sudden, overwhelming need to urinate that's difficult to defer — even when you went recently. The defining symptom of OAB. You have a short window before leakage occurs.
Urinary frequency (>8×/day)
Visiting the bathroom more than 8 times per day, often preemptively "just in case." Normal voiding is 6–8 times in 24 hours. Many OAB patients go far more.
Nocturia (waking at night)
Getting up 2 or more times during the night to urinate. This disrupts sleep cycles, causes exhaustion, and is linked to falls, cognitive decline, and cardiovascular risk over time.
Urge incontinence (leakage)
Involuntary urine loss that occurs with — or immediately after — a strong urge. Not a "weak bladder" — the bladder muscle is contracting at the wrong time due to nerve misfiring.
Bathroom mapping
Planning every outing around where bathrooms are located. Avoiding travel, restaurants, events, or long car trips because of bladder unpredictability.
Medications that didn't help
If you've tried anticholinergics (oxybutynin, tolterodine) or mirabegron without lasting relief, you're not alone — only about 1 in 8 patients achieves durable control with OAB drugs.
Common causes of overactive bladder —
though often no single cause is found.
OAB can stem from one condition or a combination. Identifying contributing factors helps guide treatment decisions.
Nerve damage or dysfunction
Trauma, surgery, neurological conditions (MS, Parkinson's, diabetes) can disrupt the nerve signals between the brain and bladder — causing the bladder to contract at the wrong time.
Urinary tract infections
A UTI can irritate the bladder's nerve lining and trigger involuntary contractions. Recurrent UTIs can produce persistent OAB-like symptoms even after infection clears.
Excess weight
Extra abdominal weight puts continuous pressure on the bladder, lowering its functional capacity and increasing urgency and frequency — especially with movement.
Estrogen decline after menopause
Hormonal changes reduce the tone of bladder and urethral tissue, contributing to urgency and leakage. This can be a significant driver of OAB in postmenopausal women.
Medications and dietary irritants
Caffeine, alcohol, diuretics, and some prescription drugs can increase urine production or irritate the bladder lining — worsening OAB symptoms. Acidic and spicy foods are common triggers.
Idiopathic (no identifiable cause)
In many cases, no single underlying cause is found. The nerve signaling dysfunction exists without a clear precipitating event. SNM can still be highly effective in these patients.
You may be a candidate
if any of these apply.
Sacral neuromodulation is most often considered when conservative therapies haven't provided enough relief. Most of our patients arrive with at least one of the following.
- ✓You experience sudden, hard-to-control urinary urgency.
- ✓You leak urine before you can reach the bathroom.
- ✓You visit the bathroom more than 8 times per day.
- ✓You wake up 2 or more times per night to urinate.
- ✓You've tried bladder medications without sufficient relief.
- ✓You stopped medications because of side effects.
- ✓You've completed pelvic floor therapy without lasting relief.
- ✓You want to test the therapy before committing to an implant.
Every patient completes a short trial — before any permanent decision.
You wear a small external test device for 1–2 weeks and go about your normal life. If you don't see meaningful improvement, the lead is removed. No implant. No pressure.
Source: ARTISAN-SNM 2-year study · Pezzella et al. (2021) · PMID 33508155
📞 480-757-8777 — Free ConsultSacral neuromodulation —
a bladder pacemaker for lasting relief
A small nerve stimulator delivers mild electrical pulses to the S3 sacral nerve, recalibrating the signals that control bladder function. We use the Axonics System (Boston Scientific) and Medtronic InterStim — both FDA-approved.
External Trial
A 1–2 week test phase using a temporary lead and external stimulator. You go about your normal life tracking whether urgency, leakage, and frequency improve. Fully reversible — if it doesn't work, the lead is removed and you've lost nothing.
Permanent Implant
If your trial confirms improvement, a small rechargeable device is implanted in a same-day outpatient procedure under local anesthesia with sedation. Many patients resume light activity the same day. Dr. McJunkin performs every implant personally.
Programming & Freedom
Settings are fine-tuned during follow-up visits over the first 4–8 weeks. The device is fully reversible and rated for 10–20 years of rechargeable battery life. Most patients report sleeping through the night within weeks.
Trial first. Always.
Every patient at Bladder Centers of America completes the external trial before any permanent device is placed. If the trial doesn't produce real improvement, we don't proceed. You are never pressured — and you're always in control of the decision.
OAB treatment options —
from first-line to best-in-class
Most patients are first offered behavioral therapy and medications. When those don't provide lasting relief, sacral neuromodulation is the most evidence-backed next step.
Behavioral & Lifestyle Therapy
Fluid management, dietary changes (eliminating caffeine, alcohol, acidic foods), bladder training, scheduled voiding, and Kegel exercises. These are always the right place to start and can reduce symptoms in some patients.
Best as first line or adjunct — limited for nerve-driven OABOAB Medications
Anticholinergics (oxybutynin, tolterodine, solifenacin) and beta-3 agonists (mirabegron). These chemically suppress bladder contractions. Side effects are common, and only about 1 in 8 patients achieves durable long-term control. Long-term anticholinergic use is linked to increased dementia risk in older adults.
~12% achieve durable control — significant side effect burdenBladder Botox (OnabotulinumtoxinA)
Injections directly into the bladder muscle that temporarily paralyze it. Effective short-term, but requires repeat injections every 6–9 months, carries a 1.55× higher adverse-event rate vs. SNM, and significantly elevated early UTI risk.
Repeat injections indefinitely · Higher adverse event rate than SNMPTNS (Percutaneous Tibial Nerve Stimulation)
Office-based electrical stimulation via a needle near the ankle. Requires 12 weekly visits, then monthly maintenance indefinitely. Only ~26% of responders maintain benefit at 3 years — and it must continue or benefit fades.
Weekly visits required indefinitely · Only 26% maintain benefit at 3yrSacral Neuromodulation (SNM)
Directly targets the S3 sacral nerve to recalibrate the signal causing OAB. FDA-approved. One-time procedure with a device lasting 10–20 years. Trial before commitment. Ranked #1 of all OAB therapies in a 17-RCT network meta-analysis — larger urgency and frequency reductions than any other treatment.
Ranked #1 in 17-RCT meta-analysis · 10–20 yr device life · Trial firstSurgery (Augmentation Cystoplasty)
A portion of the bladder is replaced with a segment of bowel to increase capacity. Reserved for severe, refractory OAB when all other therapies have failed. Major surgery with significant recovery time and potential for lifelong self-catheterization.
Last resort only — reserved for severe refractory casesRanked #1 of all therapies
in a 17-RCT meta-analysis
| Treatment | Best For | What the Evidence Shows |
|---|---|---|
| Medications | First-line OAB | Only ~1 in 8 patients achieves durable symptom control. Anticholinergics linked to increased dementia risk and falls in older adults. Require ongoing daily use. |
| Pelvic Floor Therapy | Stress / mixed symptoms | Helpful adjunct, but typically doesn't resolve neurogenic urgency or fecal incontinence on its own. |
| PTNS | Office-based, no implant | ~0.8 fewer voids/day. Weekly visits for 12 weeks, then monthly indefinitely. Only ~26% maintain benefit at 3 years. |
| Bladder Botox | OAB / urge incontinence | Effective short-term but 1.55× higher adverse-event rate and 1.58× higher early UTI risk vs. SNM. Repeat injections every 6–9 months. |
| Sacral Neuromodulation ✦ | OAB, urge incontinence, urinary retention, fecal incontinence | Ranked #1 of all therapies in a 17-RCT meta-analysis. Reduces frequency by 6.4–8.1 voids/day and incontinence by 8.9–10.96 episodes/day. Trial first, then a device rated for 10–20 years. |
Sources: Wang et al., Toxins 2020 (17-RCT network meta-analysis) · Eftekhar et al., Int Urogynecol J 2020 (SNM vs Botox) · ARTISAN-SNM study, Pezzella et al. 2021 (PMID 33508155)
Treated by the
#1 Axonics provider in the world
Provider
Dr. Tory L. McJunkin, MD
Triple Board-Certified · Sacral Neuromodulation Specialist · Former Mayo Clinic Faculty
Dr. McJunkin is a triple board-certified neuromodulation specialist, former Mayo Clinic faculty member, and the author and editor of the definitive medical textbook on sacral neuromodulation for bladder and bowel dysfunction. He is the #1 Axonics provider in the world by implant volume — having performed more Axonics SNM procedures for OAB and related conditions than any other physician on the planet.
He was a founding member of the Axonics Medical Advisory Board in 2013, helped guide the company toward FDA approval, and has trained over 1,000 physicians in neuromodulation since 2007. Every trial and every permanent implant at Bladder Centers of America is performed by Dr. McJunkin personally — no fellows, no residents, no handoffs.
No pressure. No committing
to surgery on day one.
The first visit is a conversation. Here is exactly what to expect.
Your story, in your words
We start by listening — symptom history, what you've already tried, and how OAB affects your daily life. Bring your voiding diary if you have one — or we'll give you one to start.
Honest candidacy review
Not everyone is a candidate for sacral neuromodulation. Dr. McJunkin tells you directly which therapies match your situation — including non-implant options if SNM isn't the right fit.
Clear next steps
You leave with a written plan, timing, and insurance details. Our team handles prior authorization at no cost. If you're ready to move forward, we schedule your trial that day.
Telehealth available for the initial consultation.
No need to travel for the first visit. We send the video link 24 hours before your appointment. Medicare and most major plans accepted. No referral required.
Medicare and most major plans
cover sacral neuromodulation.
No referral required. Our team handles your prior authorization and verifies your benefits before any procedure.
Blue Shield
Coverage applies when medical necessity criteria are met — typically prior failure of conservative therapy and medications. Our team verifies your benefits and handles prior authorization at no cost. Call us to verify your benefits →
Your overactive bladder questions,
answered honestly.
OAB rarely exists alone —
SNM treats the full spectrum.
Sacral neuromodulation is FDA-approved for four conditions. Most OAB patients also experience one or more of the following.
You've planned life around
the bathroom long enough.
Most patients start with a short consultation and, when appropriate, a temporary external trial before making any permanent decision. Your first appointment can be telehealth.